-+ 0.00%
-+ 0.00%
-+ 0.00%

BioXcel Therapeutics Reports Phase 3 Study Results on BXCL501 for Agitation in Bipolar Disorder and Schizophrenia at Home

Reuters·11/10/2025 15:02:41

Please log in to view news